Floatz logo

ETOPOSIDE

Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL

National Cancer Institute (NCI)Small moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL cohort.

Asset / SponsorPhaseRating
Cytosin-Arabinosid
National Cancer Institute (NCI)
Phase 2BB
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-
National Cancer Institute (NCI)
Phase 2BB
Azacitidine
National Cancer Institute (NCI)
Phase 2B
Rapamycin
Fred Hutchinson Cancer Center
Phase 2B
Fludarabine
Fred Hutchinson Cancer Center
Phase 2B

View all 14 →

Same molecule, other indications

ETOPOSIDE is also rated in:

acute megakaryoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
acute monocytic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
acute myeloblastic leukemia with maturationDormant
BBB
Indicative ·
79 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →